Asset profile
Vericiguat · Verquvo
Small molecule
Evidence outlook
Approved: Heart Failure
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
65 competitors in this universe: 0 direct rivals (same mechanism and indication), 5 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Vericiguat (Verquvo): this drug | Approved | Small molecule | Soluble guanylate cyclase | ||
| Mosliciguat | Phase 3 | Small molecule | Soluble guanylate cyclase | ||
| Riociguat (Adempas) | Phase 3 | Small molecule | Soluble guanylate cyclase | ||
| BAY3283142 | Phase 2 | Small molecule | Soluble guanylate cyclase | ||
| Praliciguat | Phase 2 | Small molecule | Soluble guanylate cyclase | ||
| SK-08 | Phase 1 | Small molecule | Soluble guanylate cyclase | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Dapagliflozin (Farxiga / Forxiga) | Approved | Small molecule | SGLT2 | ||
| Empagliflozin (Jardiance) | Approved | Small molecule | SGLT2 | ||
| Ferric Carboxymaltose (Injectafer / Ferinject) | Approved | Iron Complex (iv) | Iron repletion | ||
| Ferric Derisomaltose (Monoferric / Monofer) | Approved | Iron Complex (iv) | Iron repletion | ||
| Finerenone (Kerendia) | Approved | Small molecule | Mineralocorticoid receptor | ||
| Furosemide (subcutaneous, scPharmaceuticals) (FUROSCIX) | Approved | Small molecule | NKCC2 | ||
| Furosemide (subcutaneous, SQ Innovation) (Lasix ONYU) | Approved | Small molecule | NKCC2 | ||
| Icodextrin (peritoneal Ultrafiltration) (Extraneal) | Approved | Device Solution (peritoneal Dialysis) | Peritoneal ultrafiltration | ||
| Isosorbide Dinitrate / Hydralazine (BiDil) | Approved | Small molecule | Hydralazine/isosorbide dinitrate (fixed combination) |
…and 50 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (3)
May 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (1)
What to watch
2028 (6)
April 2028 (1)
What to watch
May 2028 (1)
What to watch
July 2028 (3)
What to watch
What to watch
What to watch
December 2028 (1)
What to watch
2029 (1)
October 2029 (1)
What to watch
2032 (1)
April 2032 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.